Evofem Biosciences, Inc. · OTC:EVFM
Evofem Biosciences — Investor Presentation (March 2025)
18 slides from Evofem Biosciences's investor presentation, Mar 24, 2025
Slide 1: Evofem Biosciences Investor Presentation March 2025
E¥OFEM BIOSCIENCES INVESTOR PRESENTATION MARCH 2025 OTCQB: EVFM
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This ins forward looking within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify forward looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,
Slide 3: Evofem: Women's Sexual and Reproductive Health Innovation
EVOFEM: WOMEN’S SEXUAL AND REPRODUCTIVE HEALTH INNOVATION U.S. biopharma company generating revenues from two FDA-approved innovative products that address unmet needs in women’s sexual and reproductive health fore! ¢ Birth Control: hormone-free, on-demand prescription contraceptive vaginal gel ¢ ¢
Slide 4: 43.3M Potential PHEXXI Users in the U.S.
phere! 43.3M POTENTIAL PHEXXI USERS IN THE U.S.+ | (lactic acid, circ acid, and potassium bitartrate) Vaginal Gel 1.8%, 1%,0.4% U.S. MARKET BY CONTRACEPTIVE METHOD" MILLIONS) 100% oe . Noe 10.3M women use non-prescription contraceptives lon-Prescription Contraceptive Non-Rx methods: barrier methods;
Slide 5: Evofem Is Leading the Revolution
EVOFEM IS LEADING THE REVOLUTION Innovative women’s reproductive and sexual health solutions THE FIRST AND ONLY ON-DEMAND, NON- HORMONAL PRESCRIPTION CONTRACEPTIVE VAGINAL GEL * Vaginal pH Modulator * Hormone-free FDA-approved for prevention of pregnancy Woman-controlled Used only when you need it B
Slide 6: MOA - PHEXXI Is a pH Modulator
MOA - PHEXXI IS A pH MODULATOR Optimal vaginal pH levels can range from 3.5 — 4.5 Allows sperm to be mobile and swim up the reproductive canal This is lower than published rates of hormonal methods, which range from 9.6% to 20.1% discontinuation due to adverse reactions MARCH 24, 2025
Slide 7: Every 1% Market Share Represents Significant Net Product Sales
EVERY 1% MARKET SHARE OF THE 43.3M WOMEN IN OUR ADDRESSABLE MARKET REPRESENTS SIGNIFICANT NET PRODUCT SALES GROSS WAC per box of 12 PHEXXI applicators Gross-to-Net Adjustments Net to Evofem per box of PHEXXI Boxes each year per woman (avg.) (60 PHEXXI applicators) ary 1, 2025. WAC: Wholesale Acquisi
Slide 8: Delivering Ongoing Net Product Sales Growth
DELIVERING ONGOING NET PRODUCT SALES GROWTH IN MILLIONS smo — FY 2020 Launched PHEXXI Sept. 2020 FY 2021 $18.2 FY 2022 FY 2023 No marketing spend since Q4 2022 $19.4 FY 2024 MARCH 24, 2025
Slide 9: PHEXXI Sales Coverage
PHEXXI SALES COVERAGE || Field Coverage (n=16) Virtual Coverage G Strategic Initiatives Student Health & Residency Programs MARCH 24, 2025
Slide 10: Activating PHEXXI Utilization with Select Patient Types
ACTIVATING PHEXXI UTILIZATION WITH SELECT PATIENT TYPES Not using a prescription contraceptive Living with depression and anxiety Postpartum mother Struggles with her weight In need of non-systemic contraception Cancer survivor Wants non-hormonal
Slide 11: Creating the Vaginal pH Modulator Category
CREATING THE VAGINAL PH MODULATOR CATEGORY Changing the contraceptive counseling conversation to make it personal feeone YASINAL pl conoom sPenMiciDe OSOGO TRACKING FERTILITY copperu> TUBALLIGATION BIRTH CONTROL IS PERSONAL. WHICH METHOD* MEETS YOUR NEEDS? CONTAINS HORMONES conreenon PATCH INDICATIO
Slide 12: The GLP-1 Opportunity
THE GLP-1 OPPORTUNITY GLP-1s include Ozempic, Wegovy, Mounjaro, and Zepbound GLP-1s may make oral birth control pills less effective at certain points in dosing schedule HCPs are to “advise females using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method of cont
Slide 13: $224.56 Million TAM - Women Using GLP-1s + OCs
$224.56 MILLION TAM -- WOMEN USING GLP-1s + OCs JP Morgan analysts forecast that 30 million people may be on GLP-1s by 2030 in the U.S. ! 2030 Forecast (U.S.) 6 30M 1 LP-1 Users Women of Reproductive Age as % of U.S. Adult Population Female GLP-1 Users of Reproductive Age xX Vv x % of Women of Repro
Slide 14: Synergistic Women's Health Acquisition
SYNERGISTIC WOMEN’S HEALTH ACQUISITION —— * Acquired in July 2024 from Lupin solosec at ya=== secnidazole * Synergistic women’s health product 2g Oral Granules ¢ Aligns with strategic focus and leverages sales force * Both SOLOSEC and PHEXXI address the vaginal biome * S20M annual net sales run rate
Slide 15: SOLOSEC: Two FDA-Approved Indications
SOLOSEC: TWO FDA-APPROVED INDICATIONS BACTERIAL VAGINOSIS (BV) IN FEMALES 12 AND OLDER ¢ BV is the most common vaginal condition in women ages 15-44 * Raises pH of the vagina, which upsets the balance of the natural vaginal BV affects microbiome and can lead to symptoms of odor and discharge 29% of
Slide 16: SOLOSEC Demonstrated Solid Growth Until COVID-19 Outbreak
SOLOSEC DEMONSTRATED SOLID GROWTH UNTIL COVID-19 OUTBREAK $20M ANNUALIZED RUN RATE FOR TREATMENT OF BV ALONE? 10.0K aaa H 9.0K 1 Bi cindesse ~100K Annualized Units/Year cl Bowe LL f--SY . Bi vores Ce Monthly TRx Volume 1) SOLOSEC was not FDA approved for the treatment of trichomoniasis until July 20
Slide 17: Strong IP
STRONG IP WITH MULTIPLE ORANGE BOOK-LISTED PATENTS plete solosec a secriazole ‘Dr. Dena Hixon, former Medical Officer in Four Orange Book -listed patents afford protection into 2033 White paper by US regulatory expert* delineates hurdles to potential generic entry stemming from PHEXXI’s localized MO
Slide 18: In Summary
IN SUMMARY We are executing our strategy to improve women’s lives through innovative sexual and reproductive health products that address unmet and underserved medical needs fe i The first and only FDA-approved hormone-free, on demand prescription contraceptive ¢ ot vaginal gel - Approved and launch
Evofem Biosciences — Investor Presentation (March 2025) on 6ix